MNPR: Monopar Therapeutics Inc. - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

Monopar Therapeutics Inc.

NASDAQ:MNPR

SummaryFactSheetFinancial
Price
$59.42
Loss Chance
58.9%
n/aJITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Sorry, the data is not yet available for this stock.
Related
Aurinia Pharmaceuticals
NASDAQ:AUPH
5.68
$15.78
37.80%
Aurinia Pharmaceuticals
NASDAQ:AUPH
5.68
$15.78
37.80%
Catalyst Pharmaceuticals
NASDAQ:CPRX
6.36
$31.34
42.70%
Exelixis
NASDAQ:EXEL
6.93
$52.99
29.91%
Fabien Corp.
NASDAQ:FBIO
1.90
$0.13
100.00%
Jitta Factors
Growth Opportunity (13)
Recent Business Performance (33)
Financial Strength (47)
Return to Shareholders (0)
Competitive Advantage (7)
Jitta Signs
Cash Conversion CycleLess than 30 days
Recent Business PerformanceEarning decline 58.14% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
n/a
100.00%
2.22
131.45%
3.06
160.82%
Biotechnology
5.68
37.80%
5.68
37.80%
6.36
42.70%
COMPANY DESCRIPTION
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
www.monopartx.com
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.